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Background: Emerging antibiotic resistance amongst clinically significant bacteria is a public health issue of
increasing significance worldwide, but it is relatively uncharacterized in Cambodia. In this study we performed
standard bacterial cultures on samples from wounds at a Non-Governmental-Organization (NGO) Hospital in
Phnom Penh, Cambodia. Testing was performed to elucidate pathogenic bacteria causing wound infections and
the antibiotic resistance profiles of bacterial isolates. All testing was performed at the Naval Medical Research
Unit, No.2 (NAMRU-2) main laboratory in Phnom Penh, Cambodia.
Methods: Between 2011–2013, a total of 251 specimens were collected from patients at the NGO hospital and
analyzed for bacterial infection by standard bacterial cultures techniques. Specimens were all from wounds and
anonymous. No specific clinical information accompanied the submitted specimens. Antibiotic susceptibility
testing, and phenotypic testing for extended-spectrum beta-lactamase (ESBL) were performed and reported
based on CLSI guidelines. Further genetic testing for CTX-M, TEM and SHV ESBLs was accomplished using PCR.
Results: One-hundred and seventy-six specimens were positive following bacterial culture (70 %). Staphlycoccus
aureus was the most frequently isolated bacteria. Antibiotic drug resistance testing revealed that 52.5 % of
Staphlycoccus aureus isolates were oxacillin resistant. For Escherichia coli isolates, 63.9 % were ciprofloxacin and
levofloxacin resistant and 96 % were ESBL producers. Resistance to meropenem and imipenem was observed in
one of three Acinetobacter spp isolates.
Conclusions: This study is the first of its kind detailing the antibiotic resistance profiles of pathogenic bacteria
causing wound infections at a single surgical hospital in Cambodia. The reported findings of this study
demonstrate significant antibiotic resistance in bacteria from injured patients and should serve to guide
treatment modalities in Cambodia.
Keywords: Bacteria, Wound infections, Microbial drug resistance, Cambodia* Correspondence: gavin.w.ford.mil@mail.mil
1Naval Medical Research Unit - No.2, Phnom Penh, Cambodia
3Department of Infectious Diseases, Walter Reed National Military Medical
Center, Bethesda, MD, USA
Full list of author information is available at the end of the article
© 2015 Hout et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hout et al. Tropical Diseases, Travel Medicine and Vaccines  (2015) 1:4 Page 2 of 11Background
Providing effective health care, in developing countries
such as Cambodia is challenged by the spread of drug
resistant pathogens [1]. Emergent resistant pathogenic
strains have demonstrated potential to quickly spread
beyond their initial geographic point of origin [2]. Well
documented examples include the spread of specific
methicillin-resistant S. aureus (MRSA) clones around
the world capable of outcompeting pre-existing local
populations [3, 4]; the emergence of Enterobacteriaceae
with resistance to carbapenems conferred by New Delhi
metallo-β-lactamase 1 (NDM-1) from India and Pakistan
[5]; and the global spread of multidrug resistant Acineto-
bacter species [6]. Another factor that fuels antibiotic re-
sistance in Cambodia is the unregulated access to
antibiotics. In addition, the quality of antibiotics is not
well regulated with a significant presence of counterfeit
drugs on the market [7, 8].
Data on antibiotic drug resistance amongst clinical sig-
nificant bacteria in Cambodia is limited to date. The signifi-
cance of the development of drug resistant motifs was
evidenced in an investigation of the prevalence of CTX-M
beta-lactamase enzymes in E. coli causing community ac-
quired urinary tract infections [9]. Another study reported
on the first documented cases of community acquired
Methicillin Resistant S. aureus (MRSA) infections in
Cambodia. In this work, seventeen children were found to
have community acquired MRSA infections. All cases were
caused by two independent MRSA clones identified by mo-
lecular characterization [10]. A recent large study into bac-
terial causes of blood stream infections at a community
hospital in Phnom Penh from 2007–2010 demonstrated
high level antibiotic resistance patterns to include an ob-
served 62.3 % resistance of E. coli isolates to ciprofloxacin,
90 % of Salmonella typhi isolates having decreased suscep-
tibility to ciprofloxacin, and 21.7 % of S. aureus isolates be-
ing resistance to methicillin [11].
The health care infrastructure in Cambodia is often not
accessible to people who lack the means to pay resulting in
inadequate care [12]. This situation can lead to the develop-
ment of chronic wounds associated with traumatic injuries
that remain untreated and which often develop polymicro-
bic infections resulting in poor outcomes.
In this study we focus on the etiologic causes of
wound infections at a Non-Governmental-Organization
(NGO) surgical hospital in Phnom Penh, Cambodia, and
describe the drug resistance profiles of those agents. Our
findings demonstrate significant antibiotic resistance in
bacteria from injured patients.
Methods
Sample collection
The Children’s Surgical Center (CSC) is a non-governmental
organization (NGO) located in Phnom Penh, Cambodia thattriages between 10,000-14,000 patients per year in all age
groups. The center serves as a terminal medical facility re-
ceiving patients from across Cambodia. Wounds seen
include both traumatic wounds (vehicle accident, deep tis-
sue burns, general lacerations) as well as surgical wounds
resulting from infections from prior surgeries.Culture
Samples were collected as part of routine clinical practice
by CSC personnel. Samples of wound exudates were taken
from the most seriously ill patients and placed in standard
culture tubes containing bacterial transport media. One
swab culture was taken from each wound and placed in
Stuarts bacterial transport media. Samples were sent with
a corresponding specimen transport form.
Samples were inoculated on blood agar, Colistin Nali-
dixic Acid Agar, and MacConkey agar for 48 hours.
Direct gram staining was performed on all samples that
came from closed wounds. For positive cultures, gram
staining and identification using standard biochemical
analyses were carried out to identify the species of isolated
bacteria (API®, Biomérieux; http://www.biomerieux-usa.
com/servlet/srt/bio/usa/dynPage?open=USA_PRD_LST
&doc=USA_PRD_LST_G_PRD_USA_5&pubparams.sfo
rm=0&lang=en). Antibiotic susceptibility testing (AST)
was done using the Kirby-Bauer method [13] and Epsil-
ometer test (E-test) method on pathogenic organisms.
ASTs were interpreted in accordance with the antibiotic
susceptibility break-points published by the Clinical La-
boratory Standards Institute (CLSI) [14, 15]. Results were
reported back to CSC by electronic mail. AST results were
reported in terms of Sensitive (S), Intermediate (I), and
Resistant (R) based on existing CLSI guidelines.ESBL testing
Phenotypic screening was performed on gram negative
bacteria suspected of expressing Extended-Spectrum
Beta-lactamases (ESBLs). E. coli, Klebsiella spp. and Pro-
teus mirabilis isolates showing reduced susceptibility to
ceftriaxone (CRO 30 μg, zone diameter of ≤ 25 mm),
ceftazidime (CAZ 30 μg, zone diameter of ≤ 22 mm), az-
treonam (ATM 30 μg, zone diameter of ≤ 27 mm) were
selected for ESBL confirmatory testing as per CLSI guide-
lines (20). Phenotypic confirmation disk diffusion testing
(PCDD) was performed on Mueller Hinton agar. Ceftazi-
dime (CAZ 30 μg), ceftazidime with clavulanic acid (CAZ/
CLA 30/10 μg), cefotaxime (CTX 30 μg), and cefotaxime
with clavulanic acid (CTX/CLA 30/10 μg) were used. These
antibiotics were obtained from Becton Dickinson, USA. A
greater than 5 mm increase in the zone of inhibition for the
CAZ/CLA and CTX/CLA containing disk versus the corre-
sponding CAZ or CTX disk was considered positive for
ESBL [16].
Hout et al. Tropical Diseases, Travel Medicine and Vaccines  (2015) 1:4 Page 3 of 11PCR
PCR based genetic detection of CTX-M, TEM and SHV
ESBLs was conducted on extracted DNA from bacterial
isolates. DNA was extracted from the isolates by
QIAamp DNA Mini Kit (cat. # 51306). A total of 2 ul of
extracted DNA was used as a template for PCR analysis.
GenAmp PCR core reagent (ABI, cat. # N808-0009) was
used to amplify the sample DNA by mix with a specific
primer set (Fig. 1) of CTX-M, TEM and SHV. PCR was
performed using primers and thermocycling conditions
as in ref [17, 18].
Data management and analysis
Samples were identified by unique numerical identifiers.
Data was double-entered and automatically reviewed with
a program that detects errors in consistency. Data was
collected, stored, and managed through the execution of
the study using MS Access® (Microsoft Inc., Redmond,
WA, USA).
Results
Standard aerobic cultures of 251 wound specimens re-
vealed 176 positive samples (70 %), with 93 (53 %) hav-
ing a single pathogen and 83 (47 %) having multiple
pathogens. S. aureus was the most frequently isolated
bacteria with 99 isolates (56 %). The following bacteria
are listed in terms of decreasing frequency of isolation:
Coagulase-negative Staphylococcus spp. (CNSS) (21 %;
38 isolates); E. coli (20 %; 36 isolates); Pseudomonas
aeruginosa (14 %; 24 isolates); Enterobacter cloacae
(7 %; 13 isolates); Proteus mirabilis (7 %; 12 isolates);
Streptococcus pyogenes (7 %; 12 isolates); Klebsiella
pneumoniae (6 %; 10 isolates). All isolated bacteria arePrimer name Primer sequence (5’ à 3’)
Bla CTX-M F ATG TGC AGY ACC AGT AAR GTK ATG GC
Bla CTX-M R TGG GTR AAR TAR GTS ACC AGA AYC AGC GG
Bla TEM F TCG GGG AAA TGT GCG CG
Bla TEM R TGC TTA ATC AGT GAG GCA CC
Bla SHV F TTA TCT CCC TGT TAG CCA CC
Bla SHV R GAT TTG CTG ATT TCG CTC GG
Fig. 1 Primers used for ESBL PCR testing; Primer names followed by the pr
ESBL gene, and the resulting product size in base pairs (bp)detailed in Table 1. A select antibiogram for isolated
bacteria of interest is provided in Table 2. These bac-
teria were selected for their high clinical relevance.
There was no resistance to the carbapenems merope-
nem or imipenem with the exception of a single A.
baumanni/calcoaceticus isolate.
Fifty-two of 99 (52.5 %) S. aureus isolates were oxacillin
resistant (MRSA). Of the 52 MRSA isolates, some main-
tained susceptibility to trimethoprim-sulfamethoxazole (32
isolates); tetracycline (27 isolates); and clindamycin (8 iso-
lates). Only one MRSA isolate was sensitive to all three of
these antibiotics, while 3 MRSA isolates were resistant to
all three. Of the 38 CNSS isolates identified, 7 isolates
underwent AST before a change in procedures classified
such species of Staphylococcus as non-pathogenic for the
remainder of the study. Of the 7 CNSS isolates that under-
went AST, 5 isolates demonstrated resistance to oxacillin.
Rates of S. aureus and CNSS resistance to oxacillin is repre-
sented in Fig. 2.
Other isolated gram positive bacteria of clinical signifi-
cance included S. pyogenes and E. faecalis. There were
12 S. pyogenes isolates, 11 of which were sensitive to
penicillin, and one that was resistant (confirmed but un-
able to perform additional testing due to resource con-
straints). There were 3 E. faecalis, all of which were
sensitive to ampicillin and vancomycin.
E. coli, Enterobacter cloacae, Proteus mirabilis, and
Klebsiella pneumoniae demonstrated significant anti-
biotic resistance as shown in Table 2 and Fig. 3. These
are all Enterobacteriaceae that are common causative
pathogens to clinical bacterial disease. They were also all
isolated at a relatively high frequency in this study mak-
ing an analysis of their associated antibiotic trends moreTarget Gene Product size (bp)
universal bla CTX-M 593
Bla TEM 972
Bla SHV 797
imer base pair sequences reported in 5’ to 3’ direction for each target
Table 1 Isolated bacteria from biological samples
No. Isolated bacteria No. of isolate
1 Staphylococcus aureus 99
2 Coagulase Negative Staphylococcus sp 38
3 Escherichia coli 36
4 Pseudomonas aeruginosa 24
5 Enterobacter cloacae 13
6 Proteus mirabilis 12
7 Streptococcus pyogenes 12
8 Klebsiella pneumoniae 10
9 Raoultella terrigena 8
10 Morganella morganii 7
11 Burkholderia cepacia 6
12 Aeromonas hydrophila/caviae 5
13 Streptococcus constellatus 5
14 Enterococcus faecalis 3
15 Streptococcus agalactiae 3
16 Acinetobacter baumannii/calcoaceticus 3
17 Bacillus sp 2
18 Corynebacterium group G 2
19 Enterococcus avium 2
20 Klebsiella oxytoca 2
21 Providencia rettgeri 2
22 Streptococcus anginosus 2
23 Streptococcus equinus 2
24 Streptococcus oralis 2
25 Aeromonas hydrophila/ caviae 1
26 Alcaligenes faecalis 1
27 Burkholderia pseudomallei 1
28 Citrobacter koseri/farmeri 1
29 Citrobacter youngae 1
30 Corynebacterium strium/ amycolatum 1
31 Edwardsiella tarda 1
32 Enterobacter aerogenes 1
33 Enterobacter avium 1
34 Group D Beta-Hemolytic Streptococci 1
35 Group G Beta-Hemolytic Streptococci 1
36 Leuconostoc spp 1
37 Pantoea spp 1
38 Proteus vulgaris 1
39 Pseudomonas fluorescens 1
40 Pseudomonas luteola 1
41 Pseudomonas stutzeri 1
42 Ralstonia pickettii 1
43 Raoultella ornithinolytica 1
44 Rhodococcus spp 1
Table 1 Isolated bacteria from biological samples (Continued)
45 Serratia liquefaciens 1
46 Streptococcus dysgalactiae ssp equisimilis 1
47 Streptococcus mitis 1
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species. Thirty of 71(42.3 %) isolates were resistant to
both ciprofloxacin and levofloxacin. Twenty-three of 36
E. coli (63.9 %) isolates had resistance to both levofloxa-
cin and ciprofloxacin. Four of 24 (16.6 %) P. aeruginosa
isolates demonstrated resistance to levofloxacin and
ciprofloxacin.
For the group of four species of gram negative bac-
teria, 65 of 71 (91.5 %) isolates were resistant to ampicil-
lin. Of these 65 isolates, only 24 isolates maintained
sensitivity to amoxicillin-clavulanic acid and ampicillin-
sulbactam. A total of 45 of 71 (63.4 %) isolates were re-
sistant to piperacillin. Four of 24 (16.6 %) P. aeruginosa
isolates were resistant to piperacillin. The beta-lactamase
inhibitor combination antibiotic piperacillin-tazobactam
was not tested in this study because it was not available.
P. aeruginosa isolates were not tested against ampicillin,
amoxicillin-clavulanic acid, or ampicillin-sulbactam as
per CLSI guidelines [14, 15].
Amongst the highlighted aerobic gram negative bac-
teria, 36 of 71 (50.7 %) isolates were resistant to the ami-
noglycoside gentamicin. Only one E. coli isolate was
resistant to amikacin, while a K. pneumoniae isolate had
intermediate resistance to amikacin. A total of 23 of 71
(32.4 %) isolates were resistant to the monobactam az-
treonam. Three of 24 (12.5 %) isolates for P. aeruginosa
were resistant to aztreonam, and 5 of 24 (20.8 %) isolates
were resistant to gentamicin, respectively. There was no
observed P. aeruginosa resistance to amikacin.
A total of 33 of 71 (46.5 %) gram negative bacterial
isolates of interest were resistant to ceftriaxone. P. aeru-
ginosa isolates had a 12.5 % and 8.3 % rate of resistance
to the anti-pseudomonal cephalosporins ceftazidime and
cefepime, respectively. The group resistance of gram
negative bacterial isolates of interest to selected antibi-
otics is represented in Fig. 3.
Sensitivity testing was performed on P. aeruginosa against
the known anti-pseudomonal antibiotics pipericillin, aztreo-
nam, ceftazidime, cefepime, gentamicin, amikacin, cipro-
floxacin, levofloxacin, meropenem, and imipenem. The
rates of resistance for P. aeruginosa and those antibiotics
were as follows: pipericillin (16.6 %); aztreonam (12.5 % re-
sistant ); ceftazidime (12.5 %); cefepime (8.3 %); gentamicin
(20.8 %); amikacin (0 %); ciprofloxacin (16.6 %); levofloxacin
(20.8 %); meropenem (0 %); imipenem (0 %). The resistance
of P. aeruginosa to particular anti-pseudomonal antibiotics
is represented in Fig. 4.





Coag Neg Staph spp E. cloacae E. coli K. pneumoniae P. mirabilis P. aeruginosa S. aureus S. pyogenes
3 38 13 36 10 12 24 99 12
Amikacin: AK S(2), R(1) S(13) R(1), I(1), S(34) I(1), S(9) S(12) S(24)
Amoxicillin-Clavulanic
Acid: AmC
R(13) R(6), I(7), S(23) R(3), I(1), S(6) R(4), S(7), I(1)
Ampicillin: AM R(12), I(1) R(33), I(1), S(2) R(10) R(10), S(2)
Ampicillin-Sulbactam: SAM S(2), I(1) R(8), S(5) R(2), I(14), S(20) R(4), S(6) R(3), I(2), S(7)
Aztreonam: ATM R(1), S(10), I(2) R(17), I(7), S(12) R(5), S(5) S(12) R(3), I(4), S(17)
Cefazolin: CZ R(13) R(25), S(11) R(5), S(5) R(3), I(4), S(5)
Cefepime: FEP R(2), S(1) R(1), S(12) R(8), I(10), S(18) R(2), I(3), S(5) S(10), I(2) R(2), S(22) R(1), S(11)
Cefoxitin: FOX R(5), S(2) R(13) R(1), I(3), S(32) R(1), S(9) S(12) R(52), S(47)
Ceftazidime: CAZ R(2), S(1) S(12), I(1) R(5), I(7), S(24) R(2), I(2), S(6) R(1), S(11) R(3), S(21)
Ceftriaxone: CRO R(2), I(1) R(3), S(9), I(1) R(24), I(1), S(11) R(5), S(5) R(1), I(1), S(10) R(9), I(9), S(6) R(2), S(10)
Cefuroxime (Sodium): CXM R(4), S(9) R(25), S(11) R(5), S(5) R(3), S(9)
Chloramphenicol: C R(3), S(4) R(4), S(9) R(20), S(16) R(6), S(4) R(9), S(3) R(7), S(92) R(5), I(4), S(3)
Ciprofloxacin: CIP R(2), S(1) R(3), S(3), I(1) R(2), I(2), S(9) R(25), S(11) R(2), I(3), S(5) R(6), I(1), S(5) R(4), S(20) R(55), S(44)
Clindamycin: CC R(4), S(1), I(2) R(53), I(7), S(39) R(1), I(3), S(8)
Erythromycin: E R(6), S(1) R(68), I(8), S(23) R(5), I(2), S(5)
Gentamicin: GM R(2), S(1) R(3), S(2), I(2) R(2), S(11) R(22), I(2), S(12) R(4), S(6) R(8), S(4) R(5), S(19) R(48), S(51)
Imipenem: IPM R(1), S(2) S(13) S(36) S(10) S(12) S(24)
Levofloxacin: LVX R(1), S(1), I(1) R(3), S(3), I(1) R(2), S(11) R(23), I(2), S(11) R(2), S(8) R(4), I(2), S(6) R(5), S(19) R(53), I(2), S(44) I(2), S(10)
Meropenem: MEM R(1), S(2) S(13) S(36) S(10) S(12) S(24)
Oxacillin : OX R(5), S(2) R(52), I(3), S(44)
Penicillin: P R(6), S(1) R(98), S(1) R(1), S(11)
Piperacilin: PIP R(2), S(1) R(4), S(9) R(32), I(2), S(2) R(6), I(2), S(2) R(4), I(2), S(6) R(4), S(20)
Tetracycline: Te R(2), S(1) R(5), S(2) R(6), S(7) R(32), S(4) R(7), S(3) R(11), S(1) R(36), I(1), S(62) R(10), I(1), S(1)
Tobramycin: NN, TM R(1), (S(2) R(4), I(1), S(19)
Trimethoprim-Sulfamethoxazole: SXT R(2), S(1) R(4), S(3) R(5), S(8) R(28), I(1), S(7) R(5), S(5) R(8), I(1), S(3) R(22), I(5), S(72)
Vancomycin: Va S(7) S(99) S(12)














Fig. 2 S. aureus and CNSS resistance to oxacillin; Relative percentages of Coagulase-negative Staphylococcus spp. (CNSS) and S. aureus isolates that
were sensitive, intermediate, and resistant to oxacillin
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pneumoniae, and 3 of 12 P. mirabilis isolates, respect-
ively, demonstrated phenotypic resistance to ceftriaxone,
ceftazidime, or aztreonam by disk diffusion that can
serve as an initial screening test for presence of ESBLs
per CLSI guidelines [16]. PCDD using cefotaxime and
ceftazidime alone and in combination with clavulanic
acid was confirmatory for 32 of 38 (84.2 %) isolates. Re-
sults for PCR testing for CTX-M, TEM, and SHV ESBL
genes in these 38 isolates is represented in (Fig. 5).
Three isolates, 2 E.coli and 1 K. oxytoca, were ESBL
screen positive, but subsequently tested negative byFig. 3 E. coli/E. cloacae/P. mirabilis/K. pneumoniae group antibiotic resistanc
sensitive, intermediate, and resistant to commonly used antibiotics with vaPCDD. Genetic screening of these isolates revealed the
presence of TEM genetic sequences in the 2 E. coli, and
CTX-M genetic elements in the K. oxytoca isolate.
Discussion
Successful treatment of wound infections requires la-
boratory analysis to identify the pathogen(s) causing the
infection. However, in resource scarce countries such as
Cambodia the ability to conduct routine diagnostic micro-
biological procedures is lacking. Throughout Cambodia
antimicrobial susceptibility information is usually unavail-
able, and inappropriate antimicrobial therapy is oftene; The relative percentages of these four Enterobacteriaceae that were
riable degrees of activity against gram negative bacteria
Fig. 4 P. aeruginosa antibiotic resistance; The relative percentages of P. aeruginosa isolates that were sensitive, intermediate, and resistant to
common antibiotics with variable degrees of anti-pseudomonas activity
Fig. 5 ESBL testing – PCDD and PCR results; E. coli, K. oxytoca, K. pneumoniae, and P. mirabilis isolates tested for presence of ESBLs by PCDD and
PCR. N is the number of isolates tested by PCDD and PCR with the percentage positive in parentheses. The ESBL genes detected by PCR are
listed for each species of bacteria tested with the number detected for each gene listed in parentheses
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ters in Kampong Thom province reported multiple in-
stances of inappropriate antimicrobial therapy, most
significantly high antibiotic use (66-100 %), polyphar-
macy (2.35 per consultation), and the unnecessary use
of injections (0.9-4.5 %) [19]. The appropriate use of
antimicrobial therapy can decrease disease duration,
prevent progression to severe disease, and increase suc-
cessful resolution of infections, whereas overtreatment
may exert selective pressure, potentially contributing to
increasing antimicrobial-resistance levels [20].
In an effort to create a longitudinal data set on the
bacterial causes of wound infections, we studied the aer-
obic bacterial causes of wound infections amongst pa-
tients at a single NGO surgical center in Phnom Penh.
Such a data set is essential in order to better characterize
emerging patterns of antibiotic resistance. Our study
contributes to a better understanding of wound infec-
tions in resource limited countries like Cambodia, and
can facilitate more informed and effective clinical prac-
tice and public health policy.
Our study demonstrated oxacillin resistance among 52
of 99 (52.5 %) S. aureus isolates. There have been mul-
tiple risk factors associated with the emergence of
Methicillin Resistant S. aureus (MRSA) in remote set-
tings such as: lack of access to clean water for frequent
bathing, high frequency of anti-microbial drug consump-
tion, and sub-standard living conditions with overcrowd-
ing [21, 22]. CSC is a highly skilled non-profit surgical
center in the capital of Cambodia, with an indigent pa-
tient population. These risk factors for emergence of
MRSA are relevant to this patient population. The US
CDC has strict definitions for a community-acquired
MRSA infection and for a hospital acquired infection
(HAI) [23]. We cannot speculate as to whether these
MRSA infections were contracted via community-
acquired mechanisms or were the result of previous
stays in other medical treatment facilities.
Specific clinical information relating to presentation,
course, or outcome for patients anonymously involved
in this study was not available. We believe the MRSA
isolates recovered for this study represent a mix of com-
munity and hospital acquired infections in this highly in-
digent patient population. Frequently patients come to
CSC when prior care at other clinics or hospitals has
failed. This salvage therapy scenario is one means by
which patients with MRSA infections, acquired through
nosocomial transmission, may present for care at CSC.
The designation of MRSA as community or hospital ac-
quired is important for the purposes of surveillance of
multi-drug resistant organisms (MDROs) as it character-
izes where such pathogens are present in the geographic
area of study. The characterization of MDROs and the
degree to which they are causing community versushospital acquired infections in Cambodia is an area de-
serving additional study both for the purposes of MDRO
surveillance and for public health benefits.
Clindamycin, trimethoprim-sulfamethoxazole, and the
tetracyclines are commonly used for coverage of skin
and soft tissue infections caused by community-acquired
MRSA. In oral formulations, they are a convenient way
to manage such infections in the ambulatory setting.
These antibiotics remain a recommendation for this in-
dication by the Infectious Disease Society of America
clinical practice guidelines [24]. Our results show re-
duced sensitivities of MRSA isolates to these antibiotics.
Only thirty-two out of 52 isolates were sensitive to
trimethoprim-sulfamethoxazole (61.5 %); 27 of 52 iso-
lates sensitive to tetracycline (51.9 %); and 8 of 52 iso-
lates sensitive to clindamycin (15.4 %). Such a situation
represents a very challenging therapeutic dilemma for
doctors and patients at a no-fee-for-service center such
as CSC where parental antibiotics active against MRSA
are prohibitively expensive.
Vancomycin resistance of S. aureus is a well known
and concerning trend. Increased prevalence of MRSA
and the subsequent increased use of vancomycin in the
treatment of MRSA infections are two driving forces be-
hind that trend [25]. There was no vancomycin resist-
ance among S. aureus isolates in our study. The lack of
access and relatively infrequent use of vancomycin could
be a factor in the absence of decreased sensitivity of S.
aureus isolates to that antibiotic.
The emergence of increasingly resistant gram negative
bacteria presents a dire situation for infected patients and
their treating physicians. The 6 ESKAPE pathogens (E. fae-
cium, S. aureus, K. pneunomiae, Acinetobacter species, P.
aeruginosa, and Enterobacter species) cause the majority of
infections in US hospitals and are recognized as some of
the most significant emerging infectious disease threats of
this century. These bacteria frequently “escape” the effects
of antibiotics. Four of the bacteria in this group are gram
negative bacilli. Gram negative bacteria are important not
only due to the numbers of infections caused, but also be-
cause substantial, even pan resistance to antibiotics is in-
creasingly observed [26].
Currently, the number of unique beta-lactamases de-
scribed from clinical isolates is estimated to be at least
1,300 [27]. Some mechanisms of resistance are an evolu-
tionary response to the pressure of antibiotic use, while
others have been demonstrated to have been present for
thousands of years [28]. Clinicians are faced with examples
of extreme resistance such as carbapenemase producing
Enterobacteriaceae [5] and K. pneumoniae [29]. In some
cases, the polymyxins such as colistin, an older class of anti-
biotics, can be employed as salvage therapy, oftentimes as
combination therapy with newer antibiotics. This clinical
scenario has generated a reluctant, but renewed interest in
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able side effect profile than newer drugs [30]. In this
study, only 1/3 A. baumannii/calcoaceticus demon-
strated resistance to meropenem and imipenem.
The fluoroquinolones are an important class of anti-
biotics prized for their broad spectrum of activity and
ease of use with equivalent bioavailability in oral versus
parental forms. Emerging resistance to these antibi-
otics is limiting their usefulness, especially in South-
east Asian countries. E. coli resistance to ciprofloxacin
increased from 45.1 % to 51 % from 2000–2005 in one
study in Thailand [31], and E. coli isolates in our study
had an even higher rate of resistance (69.4 %) to cipro-
floxacin. The 71 total isolates of E. coli, E. cloacae, P.
mirabilis, and K. pneumoniae had, as a group, a 42.3 %
rate of resistance to both ciprofloxacin and levofloxa-
cin. This alarming rate of resistance will further bur-
den the healthcare infrastructure in Cambodia in the
near term. The ease of horizontal gene transfer among
gram negative bacteria makes the spread of resistance
determinants a near certainty and continued surveil-
lance is required to address this situation in order to
develop strategies to mitigate the damage that will be
caused.
The proliferation of Extended Spectrum Beta Lacta-
mases (ESBLs) is a major factor in the antibiotic resist-
ance situation. There is no consensus definition for an
ESBL [32]. One common definition states that an ESBL
is a beta-lactamase conferring resistance or reduced
susceptibility to the oxymino-beta-lactams (ceftiaxone,
cefotaxime, ceftazidime) and aztreonam (a monobac-
tam), but is inhibited by β-lactamase inhibitors such as
clavulanic acid [33]. Globally the most prominent
ESBLs include the CTX-M-14 and CTX-M-15 en-
zymes, as well as TEM-1, TEM-2, and SHV-1 enzymes.
Out of the 35 isolates that tested positive for the ESBL
genes of interest by PCR, 16 isolates were positive for
1 gene of interest. Fifteen isolates possessed 2 genes,
and 4 isolates had all 3 genes. These 4 isolates were all
Klebsiella species. It is well known that bacteria can
harbor multiple genes of resistance simultaneously.
ESBL genes are located on large plasmids that can also
house resistance genes for fluoroquinolones, aminogly-
cosides, and trimethoprim-sulfamethoxazole [34]. For
the three isolates that were ESBL PCR positive, but
subsequently tested negative by PCDD, there could be
multiple genetic reasons for those findings. An uniden-
tified resistance mechanism could have allowed the
isolates to screen positive while mutations in essential
promoter elements for transcription of the ESBL genes
could result, ultimately, in the genes not being trans-
lated. Therefore, testing as negative in the PCCD test
while containing ESBL genetic elements. Such as sce-
nario could cause PCR (genotypic) positive testing butnegative PCCD (phenotypic) testing. This could be one
of several possible reasons for the findings.
Antibiotic coverage of P. aeruginosa is an important
consideration in multiple clinical scenarios, particularly
in the treatment of nosocomial infections. The number
of antibiotics with instrinsic activity against P. aerugi-
nosa is limited. While there were only 24 P. aeruginosa
isolates the rates of resistance to some antibiotics are
interesting. For example, the rate of resistance to cipro-
floxacin was only 16.6 % among P. aeruginosa com-
pared to 69.4 % among E. coli isolates. The relatively
low rates of resistance among P. aeruginosa isolates to
the anti-pseudomonal antibiotics tested may be a re-
flection of this indigent patient population’s lack of ac-
cess to potent antibiotics. This sort of exposure is
known to selectively pressure bacteria into resistant
phenotypes. It would be interesting to compare the re-
sults of this study to a patient population of greater
means and more access to care. Such a patient popula-
tion may have higher rates of resistance.
Limitations of this study included the fact that only
standard aerobic culturing was performed, samples
came from a single center, samples were taken from the
“most ill”, and we did not use any selection criteria,
which cause selection bias towards greater rates of re-
sistance. The hospital was admittedly a source for refer-
ral of nosocomial cases, which would also bias to a
greater likelihood of resistance. Culturing for anaerobic
bacteria was not performed, nor was more sophisticated
molecular biological techniques capable of identifying
bacterial strains not recoverable by standard culture
methods. These methods were beyond the resource
constraints of the current study. This study focused
predominantly on phenotypic demonstrations of anti-
biotic resistance (AST). Finally, the lack of associated
clinical data did not allow correlations of resistance
patterns with outcomes or risk factors. Considering the
limitations imposed, we were able to recover and iden-
tify a pathogen(s) in 176 out of 251 specimens, a posi-
tive result rate of 70.1 %.Conclusions
Our work demonstrates concerning rates of resistance
among clinically significant bacterial pathogens, with
>50 % MRSA amongst S. aureus isolates and 96 % of
E. coli isolates being ESBL producers. These results
highlight the urgent need to expand the diagnostic
microbiology infrastructure in Cambodia to enable the
characterization and tracking of resistance trends in
real time. This will in turn enable improvements in
the clinical care of bacterial infections, and the reduc-
tion of some of the pressures driving the spread of
bacterial resistance.
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